Evidence map›Paper›PMID 42400664›Full record

ReviewRheumatology international2026

Myocarditis as the first sign of SLE: a case report and review of the literature.

Chrysanthi Staveri, Sophie I Mavrogeni, Alexandros Alexopoulos, Panagiotis Chronopoulos, Stamatis-Nick C Liossis

Abstract readCase ReportsReview
In one paragraph

Review in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chrysanthi StaveriDivision of Rheumatology, Department of Internal Medicine, Patras University Hospital, 26504, Patras, Greece.ORCID http://orcid.org/0000-0002-9832-0859
Sophie I MavrogeniAghia Sophia Children's Hospital, University Research Institute of Maternal and Child Health, National and Kapodistrian University of Athens School of Medicine, 11527, Athens, Greece.ORCID http://orcid.org/0000-0003-1089-7766
Alexandros AlexopoulosPatras General Clinic ''OLYMPION S.A'', 26443, Patras, Greece.ORCID http://orcid.org/0009-0009-8911-1789
Panagiotis ChronopoulosEmergency Department, Patras University Hospital, 26504, Patras, Greece.ORCID http://orcid.org/0000-0003-1706-6084
Stamatis-Nick C LiossisDivision of Rheumatology, Department of Internal Medicine, Patras University Hospital, 26504, Patras, Greece. snliossis@med.upatras.gr.ORCID http://orcid.org/0000-0003-2511-8083

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lupus myocarditis (LM) is a rare but potentially life threatening manifestation of systemic lupus erythematous (SLE). LM may be rarely the initial presentation of SLE or ma y be presented during the course of the disease. Herein, we report a case of an adult female patient who presented with a 3-day history of abdominal pain, fever and recent onset dyspnea on exertion. Twenty-four hours later the patient developed acute heart failure went into cardiac arrest during her transfer from the internal medicine department to the CT scanner. She was intubated, an intra-aortic balloon pump was inserted, and was transferred to the intensive care unit (ICU). Based on clinical signs, laboratory parameters and cardiac imaging and after the exclusion of other causes of acute heart failure LM was diagnosed. The patient received high doses of corticosteroids and cyclophosphamide and she was improved. The vasopressors were tapered off and the intra-aortic balloon pump was removed. The patient improved and she shifted out of the ICU. The initially increased troponin levels were decreased, while the ejection fraction increased to 60% five days later. The patient was followed as an outpatient after hospital discharge. At 6 months of follow-up the she was on treatment with low doses of oral steroids, hydroxychloroquine and azathioprine and her ejection fraction is 73% without signs of active disease. No recurrences of her LM have been observed during her 32 month follow-up. Prompt recognition and aggressive immunosuppressive treatment may lead to favourable prognosis.

Indexed as

Lupus Erythematosus, SystemicMyocarditisAdultFemaleHeart FailureHumansImmunosuppressive AgentsTreatment OutcomeImmunosuppressive AgentsHeart failureLupus erythematosusMagnetic resonance imagingMyocarditisSystemic

Identifiers

PMID42400664
PMCPMC13332954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.